Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| 3Z: Zebrafish mutant model reveals novel drug candidates for ADHD | ||
| By: PR Newswire Association LLC. - 22 Nov 2022 | Back to overview list |
|
|
REYKJAVIK, Iceland, Nov. 22, 2022 /PRNewswire/ -- ADHD is a highly prevalent neurodevelopmental disorder. The first-line therapeutic for ADHD, methylphenidate, is beneficial for only a subset of patients and can cause side effects including weight loss, insomnia and hypertension. Therefore, the development of non-stimulant based therapeutics is of high importance. In a study published in the journal Neuropsychopharmacology, 3Z scientists and collaborators used a uniquely powerful genetic model and unbiased drug screen to identify novel ADHD non-stimulant therapeutics. First, it was shown that when the human ADHD risk gene Latrophilin 3 was knocked-out in zebrafish, they showed a robust hyperactive behavior, consistent with ADHD. Second, it was shown that this hyperactivity can be rescued with common on-the-market ADHD therapeutics. Finally, following a large chemical screen, five novel potential therapeutics were identified. The candidates have already entered further tests. In summary, 3Z introduced a genetic model of ADHD in zebrafish and identified five novel putative therapeutics. The findings offer a novel tool for understanding ADHD, suggest a novel mechanism for its etiology and identify novel candidate therapeutics. The study can be read here: https://www.nature.com/articles/s41386-022-01505-z 3Z´s CEO Karl Karlsson has a PhD in behavioral neuroscience and is a professor in Biomedical Engineering at Reykjavik University. Karl was extensively involved in sleep research before merging the neuroscientific and engineering skillsets to high-throughput in vivo drug screening. Discussing the significance of the findings Karl stated: "We are extremely pleased to publish these latest data. For us it represents a stepping stone towards developing much needed therapeutics for the market, and an important validation of our screening platform - that can be used for multiple neuropsychiatric disorders" To find out more, please visit www.3z.is or follow on Linkedin. CONTACT: Karl Ægir Karlsson
|
||
|
|
||
 | Back to overview list | |
View original content: